SLC2A10 and neoplasm: As shown in Figure 3, SLC2A1, SLC2A5, SLC2A10, and SLC2A11 levels tended to be higher in patients with advanced tumor stages, which shows that these molecules may be involved in the development of malignancies in LUAD patients.